An Investigation of Steroid Biosynthesis Pathway Genes in Women with Polycystic Ovary Syndrome

Overview

Journal J Hum Reprod Sci

Date 2022 Nov 7

PMID 36341008

Authors

Priyal Sharma

Manish Jain

Ashutosh Halder

Affiliations

Soon will be listed here.

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common endocrinopathy whose heterogeneous genetic basis results in a variable clinical presentation. One of the main clinical features of PCOS is hyperandrogenism which occurs due to dysregulation of ovarian and adrenal steroidogenesis.

Aims: This study aimed to investigate potentially pathogenic variants in steroidogenic genes associated with PCOS.

Settings And Design: This was a hospital-based observational study.

Materials And Methods: We recruited 51 women who presented with PCOS. Fasting blood samples were drawn from the participants and their whole-exome sequencing analysis was carried out to look for pathogenic variants involved in steroidogenic pathways. The variants were predicted for their probable deleterious effects on proteins through prediction tools. We evaluated the variants with respect to the hormonal characteristics and clinical outcomes of the patients.

Statistical Analysis Used: All variables were analysed using GraphPad Prism 8. Kruskal-Wallis -test and Fisher's exact test were used to compare clinical parameters and frequency differences among PCOS patients with and without variants.

Results: The data presented here reveal eight heterozygous exonic variants, namely CYP21A2 (p.Ala392Thr, p.Gln319Ter and p.I143N), steroidogenic acute regulatory (p.Arg53 Leu), AKR1C3 (p.Phe205Val), P450 oxidoreductase (p.Val334Ile and p.Val251Met) and HSD17B6 (p.Gly40Ser), of which three were pathogenic, and four variants of uncertain significance in 8 out of 51 patients (15.68%). The identified variants were predicted to cause protein destabilisation, thus likely contributing to the pathogenesis of PCOS. Some of the variants showed significant differences between PCOS patients and population database ( < 0.05).

Conclusion: The results of this study add to the mutational spectrum of steroidogenic genes and their association with PCOS.

Citing Articles

Custom exome panel revealed new mutations in MAPK14 and novel mutation in RUNX2 gene in patients with PCOS.

Arikan Y, Onat T Sci Rep. 2025; 15(1):2128.

PMID: 39820757 PMC: 11739400. DOI: 10.1038/s41598-024-81969-9.

CAPN2 correlates with insulin resistance states in PCOS as evidenced by multi-dataset analysis.

Luo X, Dong Y, Zheng H, Zhou X, Rong L, Liu X J Ovarian Res. 2024; 17(1):79.

PMID: 38610028 PMC: 11015649. DOI: 10.1186/s13048-024-01407-2.

References

Witchel S, Aston C . The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000; 13 Suppl 5:1315-7. View

Miller W . P450 oxidoreductase deficiency: a new disorder of steroidogenesis with multiple clinical manifestations. Trends Endocrinol Metab. 2004; 15(7):311-5. DOI: 10.1016/j.tem.2004.07.005. View

Deans R . Polycystic Ovary Syndrome in Adolescence. Med Sci (Basel). 2019; 7(10). PMC: 6835615. DOI: 10.3390/medsci7100101. View

Glintborg D, Hermann A, Brusgaard K, Hangaard J, Hagen C, Andersen M . Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab. 2004; 90(3):1347-53. DOI: 10.1210/jc.2004-1214. View

Ye W, Xie T, Song Y, Zhou L . The role of androgen and its related signals in PCOS. J Cell Mol Med. 2020; 25(4):1825-1837. PMC: 7882969. DOI: 10.1111/jcmm.16205. View

Scott R, Miller W . Genetic and clinical features of p450 oxidoreductase deficiency. Horm Res. 2008; 69(5):266-75. DOI: 10.1159/000114857. View

Hershkovitz E, Parvari R, Wudy S, Hartmann M, Gomes L, Loewental N . Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J Clin Endocrinol Metab. 2008; 93(9):3584-8. PMC: 2567854. DOI: 10.1210/jc.2008-0051. View

Qin K, Ehrmann D, Cox N, Refetoff S, Rosenfield R . Identification of a functional polymorphism of the human type 5 17beta-hydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005; 91(1):270-6. PMC: 1522092. DOI: 10.1210/jc.2005-2012. View

Kaur R, Kaur T, Kaur A . Genetic association study from North India to analyze association of CYP19A1 and CYP17A1 with polycystic ovary syndrome. J Assist Reprod Genet. 2018; 35(6):1123-1129. PMC: 6030014. DOI: 10.1007/s10815-018-1162-0. View

10.

Finkielstain G, Chen W, Mehta S, Fujimura F, Hanna R, Van Ryzin C . Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2010; 96(1):E161-72. PMC: 3038490. DOI: 10.1210/jc.2010-0319. View

11.

Witchel S, Azziz R . Nonclassic congenital adrenal hyperplasia. Int J Pediatr Endocrinol. 2010; 2010:625105. PMC: 2910408. DOI: 10.1155/2010/625105. View

12.

Chaudhary H, Patel J, Jain N, Joshi R . The role of polymorphism in various potential genes on polycystic ovary syndrome susceptibility and pathogenesis. J Ovarian Res. 2021; 14(1):125. PMC: 8466925. DOI: 10.1186/s13048-021-00879-w. View

13.

De Leo V, Musacchio M, Cappelli V, Massaro M, Morgante G, Petraglia F . Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016; 14(1):38. PMC: 4947298. DOI: 10.1186/s12958-016-0173-x. View

14.

Hardiman P, C Pillay O, Atiomo W . Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003; 361(9371):1810-2. DOI: 10.1016/s0140-6736(03)13409-5. View

15.

Sahakitrungruang T, Huang N, Tee M, Agrawal V, Russell W, Crock P . Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. J Clin Endocrinol Metab. 2009; 94(12):4992-5000. PMC: 2795645. DOI: 10.1210/jc.2009-1460. View

16.

Fukami M, Homma K, Hasegawa T, Ogata T . Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development. Dev Dyn. 2012; 242(4):320-9. DOI: 10.1002/dvdy.23892. View

17.

Qiao J, Feng H . Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2010; 17(1):17-33. PMC: 3001338. DOI: 10.1093/humupd/dmq032. View

18.

Goodarzi M, Jones M, Antoine H, Pall M, Chen Y, Azziz R . Nonreplication of the type 5 17beta-hydroxysteroid dehydrogenase gene association with polycystic ovary syndrome. J Clin Endocrinol Metab. 2007; 93(1):300-3. PMC: 2190745. DOI: 10.1210/jc.2007-1712. View

19.

Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R . The genetic basis of polycystic ovary syndrome. Hum Reprod. 1998; 12(12):2641-8. DOI: 10.1093/humrep/12.12.2641. View

20.

Yildiz B, Bolour S, Woods K, Moore A, Azziz R . Visually scoring hirsutism. Hum Reprod Update. 2009; 16(1):51-64. PMC: 2792145. DOI: 10.1093/humupd/dmp024. View